Literature DB >> 24211022

Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor.

Hui Xiong1, Melinda Foulk, Lisa Aschenbrenner, Jun Fan, Choi-Lai Tiong-Yip, Kenneth D Johnson, Demetri Moustakas, Paul R Fleming, Dean G Brown, Minli Zhang, Douglas Ferguson, Dedong Wu, Qin Yu.   

Abstract

Targeting viral polymerases has been a proven and attractive strategy for antiviral drug discovery. Herein we describe our effort in improving the antiviral activity and physical properties of a series of benzothienoazepine compounds as respiratory syncytial virus (RSV) RNA polymerase inhibitors. The antiviral activity and spectrum of this class was significantly improved by exploring the amino substitution of the pyridine ring, resulting in the discovery of the most potent RSV A polymerase inhibitors reported to date.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  Antiviral; Polymerase inhibitor; Respiratory syncytial virus

Mesh:

Substances:

Year:  2013        PMID: 24211022     DOI: 10.1016/j.bmcl.2013.10.018

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

1.  Pd-catalyzed arylation of linear and angular spirodiamine salts under aerobic conditions.

Authors:  Sean W Reilly; Nikaela W Bryan; Robert H Mach
Journal:  Tetrahedron Lett       Date:  2016-12-23       Impact factor: 2.415

2.  Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen.

Authors:  Jeremy R Duvall; Lynn VerPlank; Barbara Ludeke; Sarah M McLeod; Maurice D Lee; Karthick Vishwanathan; Carol A Mulrooney; Sebastian Le Quement; Qin Yu; Michelle A Palmer; Paul Fleming; Rachel Fearns; Michael A Foley; Christina A Scherer
Journal:  Antiviral Res       Date:  2016-04-06       Impact factor: 5.970

3.  Respiratory Syncytial Virus Inhibitor AZ-27 Differentially Inhibits Different Polymerase Activities at the Promoter.

Authors:  Sarah L Noton; Kartikeya Nagendra; Ewan F Dunn; Michael E Mawhorter; Qin Yu; Rachel Fearns
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

4.  Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.

Authors:  Matthew Coates; Daniel Brookes; Young-In Kim; Heather Allen; Euan A F Fordyce; Elizabeth A Meals; Thomas Colley; Claire-Lise Ciana; Guillaume F Parra; Vladimir Sherbukhin; Jennifer A Stockwell; Jennifer C Thomas; S Fraser Hunt; Lauren Anderson-Dring; Stuart T Onions; Lindsey Cass; Peter J Murray; Kazuhiro Ito; Pete Strong; John P DeVincenzo; Garth Rapeport
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  Characterization of a respiratory syncytial virus L protein inhibitor.

Authors:  Choi-Lai Tiong-Yip; Lisa Aschenbrenner; Kenneth D Johnson; Robert E McLaughlin; Jun Fan; SreeRupa Challa; Hui Xiong; Qin Yu
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

6.  Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex.

Authors:  Robert M Cox; Mart Toots; Jeong-Joong Yoon; Julien Sourimant; Barbara Ludeke; Rachel Fearns; Elyse Bourque; Joseph Patti; Edward Lee; John Vernachio; Richard K Plemper
Journal:  J Biol Chem       Date:  2018-09-11       Impact factor: 5.157

7.  Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses.

Authors:  Jimin Xu; Wenzhe Wu; Haiying Chen; Yu Xue; Xiaoyong Bao; Jia Zhou
Journal:  Bioorg Med Chem       Date:  2021-04-18       Impact factor: 3.461

8.  Quantitative investigation of the affinity of human respiratory syncytial virus phosphoprotein C-terminus binding to nucleocapsid protein.

Authors:  Adam B Shapiro; Ning Gao; Nichole O'Connell; Jun Hu; Jason Thresher; Rong-Fang Gu; Ross Overman; Ian M Hardern; Graham G Sproat
Journal:  Virol J       Date:  2014-11-19       Impact factor: 4.099

9.  Optimization of potent and selective quinazolinediones: inhibitors of respiratory syncytial virus that block RNA-dependent RNA-polymerase complex activity.

Authors:  Daljit S Matharu; Daniel P Flaherty; Denise S Simpson; Chad E Schroeder; Donghoon Chung; Dan Yan; James W Noah; Colleen B Jonsson; E Lucile White; Jeffrey Aubé; Richard K Plemper; William E Severson; Jennifer E Golden
Journal:  J Med Chem       Date:  2014-12-04       Impact factor: 7.446

10.  Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication.

Authors:  B Bailly; C-A Richard; G Sharma; L Wang; L Johansen; J Cao; V Pendharkar; D-C Sharma; M Galloux; Y Wang; R Cui; G Zou; P Guillon; M von Itzstein; J-F Eléouët; R Altmeyer
Journal:  Sci Rep       Date:  2016-05-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.